Melbourne, May 5, 2008 AEST (ABN Newswire) - Mesoblast Limited (ASX:MSB)(US:MBLTY) Announce Research Note By ABN AMRO
Research note key outlook take-aways:
- MSB to accelerate Phase II spinal fusion trial
- Positive result of osteoarthritis trial
- Free upside from heart research
- Strong levels of cash
- Strong levels of IP protection
- Buy maintained, price target decreased to A$1.50
- Belief that MSB is most likely to partner with an orthopaedic firm to take MPCs to market.
- Should the technology prove scaleable, believe MSB may become an acquisition target for an orthopaedic company.
For the full report please visit the following link:
http://mesoblast.com/investor_analysis.php
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
M: +61 (0) 419 228 128
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com
| ||
|
